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Abstract: Proteomics is a rapidly advancing ﬁ  eld not only in the ﬁ  eld of biology but also in translational cancer research. 
In recent years, mass spectrometry and associated technologies have been explored to identify proteins or a set of proteins 
speciﬁ  c to a given disease, for the purpose of disease detection and diagnosis. Such biomarkers are being investigated in 
samples including cells, tissues, serum/plasma, and other types of body ﬂ  uids. When sufﬁ  ciently reﬁ  ned, proteomic tech-
nologies may pave the way for early detection of cancer or individualized therapy for cancer. Mass spectrometry approach-
es coupled with bioinformatic tools are being developed for biomarker discovery and validation. Understanding basic 
concepts and application of such technology by investigators in the ﬁ  eld may accelerate the clinical application of protein 
biomarkers in disease management.
Keywords: Proteomics, Mass spectrometry, Cancer, Biomarkers. 
Abbreviations: 2DE: two-dimensional gel electrophoresis; ABPP: activity-based protein proﬁ  ling; CEA: carcinoembry-
onic antigen; CI: conﬁ  dence interval; ESI: electrospray ionization; FP: fluorophosphonate; HPLC: high performance liquid 
chromatography; ICAT: isotope coded afﬁ  nity tags; IEF: isoelectric focusing; iTRAQ: isobaric tags for relative and absolute 
quantiﬁ  cation; LCMS: combined liquid chromatography-mass spectrometry; LCMSMS: liquid chromatography tandem 
mass spectrometry; LOD: limit of detection; m/z: mass to charge ratio; MALDI: matrix-assisted laser desorption ionization; 
MS: mass spectrometry; MUDPIT: multidimensional protein identiﬁ  cation technology; NAF: nipple aspirate ﬂ  uid; PMF: 
peptide mass ﬁ  ngerprinting; PSA: prostate speciﬁ  c antigen; PTMs: post-translational modiﬁ  cations; RPMA: reverse phase 
protein microarray; SELDI: surface enhanced laser desorption ionization; TOF: time-of-ﬂ  ight.
Introduction
Cancer is a prevalent and serious public health problem not only in the United States and also world-
wide. It is a major source of morbidity, and the second leading cause of death in the American popula-
tion. A total of 1,444,920 new cancer cases and 559,650 deaths are projected in the United States in 
2007 (Jemal et al. 2007). When deaths are aggregated by age, cancer has surpassed heart disease as the 
leading cause of death in individuals 85 years age or younger since 1999 (Jemal et al. 2007). 
Before cancer prevention becomes a reality, early detection and better treatment remain the hope for 
all cancer patients. It is easy to understand that the test for early detection of cancer is best done in blood 
or other types of body ﬂ  uids; however, cancer classiﬁ  cation and management are frequently accom-
plished by using tissues, as it truly represent the source for a much more reliable discrimination between 
different types and subtypes of cancer. Protein biomarkers in blood or tissues may therefore play an 
important role in cancer detection, monitoring and treatment.
Proteomics is a rapidly advancing ﬁ  eld brought about in large part because of the recent develop-
ments in mass spectrometry and associated technologies. These developments allow for the fast and 
reliable detection, identiﬁ  cation and relative quantitation of proteins. The measurements can be made 
from the solid and solution states, and sometimes from complex mixtures. The amount of protein required 
for these measurements has been continuously reducing, and today many laboratories have demonstrated 348
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the ability to obtain results from samples with 
protein concentration as low as 5 femtomoles 
(about 3 × 10
–10 grams of albumin, for example). 
Emerging from this work is a new goal in clinical 
research to use these techniques to discover and 
identify proteins that are speciﬁ  c to, and diagnostic 
for, a given disease. If successful, these develop-
ments will ultimately allow for early detection and 
possibly individualized therapy for the disease. 
The object of this review is to describe the basic 
concepts, tools, limitations and progress in this 
rapidly advancing ﬁ  eld. The obvious potential of 
protein biomarker screening for cancer diagnosis 
has yet to be fully realized. The clinical application 
of proteomics to cancer management will not be 
successful until well controlled investigations with 
standardized methods of proven accuracy for 
profiling nanogram level proteins in complex 
mixture of biological specimens.
Why protein biomakers?
There are many reasons why proteins are important 
or even to be better biomarker than other molecules 
such as DNA or RNA. Firstly, proteins are much 
more diverse than nucleic acids and therefore carry 
more information. Through alternative splicing and 
over 100 unique post-translational modiﬁ  cations 
(PTMs) including covalent modification by 
attachment of speciﬁ  c functionalities (acetylation, 
phosphorylation, etc), as well as post-translational 
trimming and cleavage of proteins by site-speciﬁ  c 
proteases, tens and possibly hundreds of distinct 
protein species can result from expression of a 
single gene. Moreover, many cellular functions are 
not revealed at the level of the nucleic acids, but 
are manifested by the PTMs, as well as cleavage 
of proteins by site-specific proteases. With a 
limited number of human genes (~20,000) and 
many more proteins (10
5–10
6) (Stein 2004; Pennisi 
2003), the latter are likely to more closely reﬂ  ect 
the complex nature of cellullar biology and host 
physiology. Secondly, fluctuating levels of an 
mRNA transcript make the correlation with the 
amount of protein synthesized inconsistent in many 
cases. For example, when the same cells or tumors 
were examined by both cDNA arrays and 
proteomic analysis, the concordance rates were 
low between the mRNA transcript proﬁ  les and 
corresponding protein expressional patterns 
(Anderson and Seilhamer, 1997; Alaiya et al. 
2000a; Chen et al. 2003; Nishizuka et al. 2003). 
Therefore studies limited to the DNA or mRNA 
analysis may reﬂ  ect only a partial assessment of 
cellular function. Documenting proteins and their 
interactions in cancer cells represents a comple-
mentary and much more comprehensive approach 
to understanding the cellular changes caused by 
disease processes. 
Deﬁ  nitions
A “biomarker” is deﬁ  ned as a measurable analyte 
that correlates with a speciﬁ  c phenotype, such as 
a normal biological condition, a pathological 
process, or a pharmacological response to a thera-
peutic intervention (Group, 2001). A biomarker is 
unique in that it distinguishes and discriminates 
between comparative biological conditions such 
as cancer and non-cancer. “Cancer proteomics” is 
deﬁ  ned as molecular proﬁ  ling of cancer-associated 
proteins approached by analyzing the global 
protein expression patterns of tumor cells or extra-
cellular ﬂ  uids such as serum from cancer patients 
(Alaiya et al. 2000b). To date there have been many 
candidate proteomic biomarkers suggested for 
various types of cancer. However, none has yet met 
the stringent requirements for clinical use, such as 
reproducibility, speciﬁ  city and sensitivity. A true 
biomarker should be conﬁ  rmable across laborato-
ries and technology platforms (Aebersold et al. 
2005), in its ability of predicting the clinical state. 
Today the greatest need in cancer proteomics 
research lies in improvement in the methodology 
and technology for the recognition and identiﬁ  ca-
tion of reliable protein biomarkers speciﬁ  c for the 
disease or biology of the disease. 
Historically, biomarker discovery was domi-
nated by targeted approaches, in which candidates 
derived from biological knowledge were selec-
tively evaluated for their correlations with clinical 
conditions (Gillette et al. 2005). However, in the 
past two decades, the advances in new mass spec-
trometric ionization techniques for discovering 
macromolecules has revolutionized biomarker 
research (Karas and Hillenkamp, 1988). Now for 
the ﬁ  rst time it is possible to display complex 
protein proﬁ  les in convenient one- and two-dimen-
sional formats, and at the same time identify the 
proteins. More and more studies are employing 
mass spectrometry technology to search for novel 
cancer biomarkers. Reﬂ  ecting this trend, in March 
2007, a MedLine search for the words “cancer 
biomarker” listed in 119,912 publications, while 349
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a similar simultaneous search that included the 
word “protein” resulted in 96,598 articles. A selec-
tion of published representative studies on cancer 
biomarkers using mass spectrometry technique 
are summarized in Table 1. However, as reported 
by Alaiya et al. (2005), the lack of proteomics 
markers for cancer stands in sharp contrast to the 
signiﬁ  cant progress that has been made in the 
discovery of gene-based biomarkers during the 
last 20 years. This disparity also reflects the 
increased difficulty when working with the 
proteome as opposed to the genome. Nevertheless, 
the potential offered by proteomic technology in 
biomarker discovery draws research support from 
both government funding agencies and private 
sector.
A protein biomarker detected by mass spectrom-
etry can be a single entity (with protein identiﬁ  cation, 
therefore identity-based) or a suite of entities (protein 
signatures, therefore pattern-based). For the biomarker 
to be clinically useful, the abundance or change in 
abundance of speciﬁ  c proteins must reﬂ  ect some 
aspects of normal physiology/biochemistry or a 
disease process. Combined liquid chromatography-
mass spectrometry (LCMS) is the technique to which 
most cancer proteomic research is now gravitating. 
Because of the direct on-line link between chroma-
tography and mass spectrometry, this technique can 
more easily accommodate complex biological samples 
such as serum and plasma. In contrast, the enthusiasm 
which originally greeted other techniques that do not 
use direct on-line chromatography, such as surface 
enhanced laser desorption mass spectrometry 
(SELDI), has now waned. This has occurred as the 
need for chromatography when dealing with complex 
samples, such as serum and plasma, has become 
obvious. In this context then, as defined here, a 
biomarker may be a peak or peaks detected on a 
chromatogram, a signal or signals in a mass spectrum, 
or a feature or features in a three dimensional repre-
sentation of peak retention times, signal mass to charge 
(m/z) ratios and intensities. These are three different 
representations of LCMS data that are routinely 
acquired in proteomic analyses.
It has been pointed out that the utility of a 
protein biomarker for disease diagnosis or detec-
tion does not necessarily require knowledge of the 
identity of the protein or proteins involved (Petri-
coin et al. 2002; Villanueva et al. 2005), so long 
as the pattern of peaks, signals or features are 
sufﬁ  ciently reproducible to reﬂ  ect the present 
disease. Strictly speaking, this could be the case. 
However, without knowing the identity of the 
biomarker proteins, information related to the 
underlying disease process will not be forthcoming. 
Furthermore, the identity of the protein or proteins 
involved is necessary for independent validation 
of the biomarker by different technologies, and for 
the future development of faster, cheaper and more 
reliable assays (which probably will not rely on 
chromatography or mass spectrometry). Conse-
quently, disease-based protein biomarker research 
involves both recognition of the biomarker signa-
ture and identiﬁ  cation of the proteins involved.
A dilemma—low- and high-
abundance proteins
The components of complex samples (proteomes) 
are typically present in a wide concentration range. 
The components of human plasma and serum for 
example extend across 10–12 orders of magnitude 
in concentration (Anderson and Anderson 2002). 
This presents an analytical dilemma because no 
one technique has a dynamic range that can accom-
modate such samples. In the case of cancer 
biomarker screening, while the results of some 
investigations (Li et al. 2005, Yu et al. 2004) 
suggest that high abundance proteins such as 
Complement C3a (desArg) (a 77-amino acid 
protein) and a C-terminal-truncated form of C3a 
may be useful for diagnosing breast cancer, and 
β-globin for colorectal cancer, the low speciﬁ  city 
of these tests limits their clinical utility. At the same 
time, the most clinically useful cancer biomarkers 
are low-abundance molecules; like prostate speciﬁ  c 
antigen (PSA) (Wang et al. 1979; Stamey et al. 
1987), members of the mucin family of proteins 
(for example, CA 15.3), carcinoembryonic antigen 
(CEA) and cytokeratins (i.e. TPA, TPS and Cyfra 
21.1; Seregni 2004) being examples. Interestingly, 
all these established cancer biomarkers are glyco-
proteins. In addition, the alteration in protein 
glycosylation which occurs through varying the 
heterogeneity of glycosylation sites or changing 
glycan structure of proteins on the cell surface and 
in body ﬂ  uids have been shown to correlate with 
the development of cancer and other disease states 
(Durand and Seta, 2000). Therefore, the technology 
for screening protein biomarkers in body ﬂ  uids 
must confront the large dynamic range of the 
concentration of the molecules of interest. Thus to 
accommodate both low- and high-abundance 
molecules, there is a need for fractionation of 350
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Table 1. Summary of selected MS-based cancer biomarker studies. 
Cancer type  Specimen  Diagnostic sensitivity and   MS technology  Reference
   speciﬁ  city or protein ID
Breast  Serum  93%; 91% Complement   SELDI-TOF, Tandem   Li et al. 2002, 2005
   component  C3adesArg and  mass peptide 
    its truncated form  sequencing
Breast  Ductal   75%  SELDI-TOF  Mendrinos et al.   
       2005
 lavage
Breast Nipple    Hb-β chain  SELDI-TOF  Sauter et al. 2005
 aspirate
  ﬂ  uid
Breast  Serum  High molecular weight   SELDI-TOF  Heike et al. 2005
   kininogen,  apolipoprotein  A-II.
Breast  Serum  94%; 81.3%  2DE, LCMSMS  Ru et al. 2006
Breast  Nipple   Vitamin D binding protein et al..  ICAT MSMS  Pawlik et al. 2006
 aspirate
  ﬂ  uid
Breast  Cell line  14-3-3 sigma  MALDI  Liu et al. 2006
Breast  Tissue  Thymosin alpha-1  HPLC and MALDI  Traub et al. 2006
Breast  Nipple   8 markers with m/z – 5061,   SELDI-TOF MS  He et al. 2007
  aspirate   5994, 6001, 10207, 13070, 
  ﬂ  uid  13436, 13447, 57075
Breast  Tissue  >1000 protein identiﬁ  ed  NanoLC MS  Umar et al. 2007
Ovarian  Serum  100%; 95%  SELDI-TOF  Petricoin et al. 2002
Ovarian  Serum  73–96%; 83–95%  SELDI-TOF  Kozak et al. 2003
Ovarian  Serum  Haptoglobin-alpha subunit  SELDI-TOF  Ye et al. 2003
Ovarian  Serum  Apolipoprotein A1, truncated   SELDI-TOF  Zhang Z et al. 2004
    form of transthyretin, fragment 
    of inter-alpha trypsin inhibitor 
    heavy chain H4. 74%; 97%
Ovarian  Serum  Transthyretin and its fragment,     Kozak et al. 2005
    beta-hemoglobin, apoAI,   Micro-LCMSMS
   and  transferrin
Ovarian  Serum  Hemoglobin-alpha and -beta  SELDI-TOF  Woong-Shick et al.  
       2005
Ovarian  Plasma  94%  SELDI-TOF  Rai et al. 2002
Ovarian  Plasma  Amyloid A1 and its truncated  SELDI-TOF  Moshkovskii et al.
   form    2005
Ovarian  Plasma  90–96.3%; 100%  SELDI-TOF  Lin et al. 2006
Ovarian Plasma  ﬁ  brinopeptide-A  2DE, MS  Ogata et al. 2006
Endometrial  Tissue  95%, chaperonin 10, a-1-  LCMSMS, Q-STAR  Desouza et al. 2007
   antitrypsin
Colorectal  Serum  95.2%, 90.0%  MALDI-TOF  De Noo et al. 2006
Colorectal Cell  line Prothymosin  α  SELDI-TOF  Shiwa et al. 2003
Colorectal  Serum  N-terminal fragment of   SELDI-TOF  Engwegen et al.    
       2006
    albumin, apoC-I, apoA-I
Colorectal Serum  β-defensins  SELDI-TOF  Melle et al. 2005
Colorectal Tissue,   β-defensins  SELDI-TOF  Albrethsen et al.  
 serum      2005
Colorectal  Tissue  Hydrophobic proteins   2DE, MALDI-TOF  Alvarez-Chaver et al. 
   (vimentin)  /TOF,  ESI–MSMS  2006
Prostate  Serum  Zn-alpha2 glycoprotein (ZAG)  LCMSMS  Bondar et al. 2007351
Cancer Biomarker Discovery by Mass Spectrometry
Biomarker Insights 2007:2 
complex samples. While undesirable because it 
increases the workload and introduces additional 
error in the measurements, this seems unavoidable. 
One current research focus is how best to frac-
tionate complex proteomes, and many different 
strategies are now being compared. 
Application of proteomic 
technologies to cancer
Early detection of cancer
It is well known that early detection of cancer can 
lower the mortality rate. Cancers diagnosed at an 
early stage are more likely to be cured by 
conventional therapy. For many cancers, 5 and 
even 10-year survival may approach or even 
exceed 90% if treated early, and only 10% or less 
when found late (Etzioni et al. 2003). The Pap 
smear test (named after the inventor Georgios 
Papanicolaou) for early detection of pre-neoplastic 
cervical cancer (Shingleton et al. 1995), and colo-
noscopy for early detection of colon cancer 
(Winawer et al. 1995; Winawer, 2001), are good 
examples of how early disease detection can 
signiﬁ  cantly improve cancer outcome. Not surpris-
ingly, the focus therefore in biomarker screening 
is to identify proteins that can aid in early detection 
and diagnosis of the disease. 
Similar to other cancers, the early detection of 
breast cancer by serum biomarkers currently 
remains a research quest. The circulating breast 
cancer markers now used in clinical practice (CA 
15.3, CEA and cytokeratins) are useless in early 
detection since they are all associated with a large 
tumor burden at late stage of the disease (Seregni 
et al. 2004). It is estimated that a minimum number 
of 10
9 tumor cells are required for breast cancer 
detection by the current methods such as mammog-
raphy or clinical breast examination (Dummin et al. 
2006). Therefore the challenge is to develop tech-
niques that can detect specific disease-related 
changes from cells fewer than 10
9 cells or a total 
mass equivalent to milligrams of tissues. Fortu-
nately, the ﬁ  eld of cancer biomarker screening is 
evolving rapidly, and recent developments in the 
technological, biological and statistical realms 
show promise for uncovering markers that meet 
this goal. 
In 2002, Petricoin et al. made a sensational 
report of mass spectrometry/proteomics-based 
methods for the detection of ovarian cancer. In this 
work SELDI mass spectrometry was used to proﬁ  le 
serum proteins, the pattern of which could be used 
to separate cancer from non-cancer patients. One 
claim was that the technology could be used for 
early detection of ovarian cancer. In the study, a 
preliminary “training” data set, consisting of 
spectra derived from the analysis of serum from 
50 unaffected women, and 50 patients with ovarian 
cancer, was analyzed by an interactive pattern-
recognition algorithm. A pattern was identiﬁ  ed that 
discriminated cancer from non-cancer. The pattern 
was then used to classify an independent set of 
spectra obtained from 116 masked serum samples 
collected from 50 women with ovarian cancer, and 
66 unaffected women. The pattern identiﬁ  ed in the 
training set successfully segregated cancer from 
non-cancer in the second set of samples. The vali-
dation set correctly identiﬁ  ed all 50 ovarian cancer 
cases, including all 18 stage I cases. Of 66 cases 
of non-malignant disease, 63 were classified 
correctly, giving a sensitivity of 100% (95% conﬁ  -
dence interval (CI) 93–100%), a speciﬁ  city of 95% 
(CI of 87–99%), and a high positive predictive 
value of 94% (CI of 84–99%). 
Since publication of this report, there have been 
several attempts to repeat, conﬁ  rm and extend these 
ﬁ  ndings to other types of cancer. These newer 
investigations have used similar proteomic 
proﬁ  ling approaches with body ﬂ  uids from patients 
with various types of cancer (Adam et al. 2002; Li 
et al. 2002; Borozdenkova et al. 2004; Ebert et al. 
2004, Li et al. 2005; Mendrinos et al. 2005; Villan-
ueva et al. 2005). Unique biomarker patterns have 
been reported for early detection of ovary, prostate, 
breast, and thyroid cancer. The enthusiasm led to 
the postulation that a new era in cancer diagnostics 
had come, in which serum proteomic proﬁ  ling 
would meet the goal of early cancer detection. 
However, several methodological and bioinfor-
matic artifacts and biases have been identiﬁ  ed, 
which challenged the validity of the published 
results (Baggerly et al. 2005; Diamandis and van 
der Merwe, 2005). While it appears that all have 
high diagnostic sensitivities and speciﬁ  cities, few 
of the reported biomarkers have adequate repro-
ducibility (Diamandis, 2002). In retrospect it 
appears that the limitations of these initial efforts 
to identify reliable diagnostic cancer biomarkers 
resulted from differences in methodology among 
the investigators. 
Like almost every newly emerged technology, 
through these early efforts including errors and 352
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fails in searching disease associated biomarkers, 
much has been learned to pave the way for true 
biomarker discovery. The expectation to the new 
technique frequently exceeds the capacity at the 
moment. On the other hand, the unfulﬁ  lled expec-
tations or the aware limitations of the technique 
are the forces to drive the research forward. 
In the foreseeable future, the field will be 
continuously challenged by the heterogeneous 
nature of the disease, the specimen and the tech-
nology. It is quite often the case that the hetero-
genesis of patients, such as gender, age, genetics, 
ethnicity, body mass, medication, the presence of 
other conditions and diseases, emotional stress, 
menopausal status, and dietary/nutritional prefer-
ences, as well as sample preparation, may all 
introduce artifacts. Also, given the small quantity 
of the human specimens and the limited availability 
of quality samples, and the extraordinary cost of 
proteomics technologies, many studies are based 
on small numbers of samples or even pooled 
samples. Thus, with small sample numbers, it is 
reasonably expected that the overlap of ﬁ  ndings 
among different groups would be low. As progress 
being made rapidly, the ﬁ  ndings would eventually 
grow together. To make the matter even more 
complex, the mass spectrometry platforms and 
methodology used drastically could be different 
among research groups. Even if the instruments 
are same, they could be operated in very different 
modes for which those details are not disclosed in 
publications. Thus, the MS methodologies used 
are as heterogenous as cancer disease itself. Taking 
together, it becomes clear that consistent ﬁ  ndings 
amongst laboratories can only accomplished 
after. 
Another fundamental problem, as already 
mentioned, lies in the enormous number and 
10
9concentration range of proteins in tissues and 
body ﬂ  uids and the complexity of these ﬂ  uids. 
Compared with MS techniques, current cancer 
markers identiﬁ  ed by immunological techniques 
are at subnanogram levels, and have no cross-reac-
tivity in the presence of a huge excess of other 
unrelated proteins. Immunological techniques 
avoid the need for removal of high abundance 
proteins before nanoscale detection of the target 
analyte. However, compared with immunological 
techniques, the unique promise of proteomics 
results from its potential to simultaneously resolve 
and compare thousands of proteins for qualitative 
and quantitative differences prior to identiﬁ  cation 
by mass spectrometry. This technology will 
become a powerful diagnostic tool once methods 
are developed to ﬁ  rst separate high, medium, and 
low abundance proteins before proteomics analysis 
of each of these three subsets using the more than 
1,000-fold dynamic range capability of mass 
spectrometry. 
Proteomics in cancer prognostics 
and monitoring response to therapy
Increased serum levels of proteins like CEA and 
PSA are used to detect re-growth of some common 
malignancies after conventional therapy including 
surgery, radiation, and chemotherapy. Progression 
of nearly all tumors results from induction of 
inﬂ  ammatory cytokines, growth factors, angio-
genic peptides like VEGF, and release of high 
abundance coagulation proteins in the blood that 
stimulate cancer cell proliferation and metastasis. 
Many of these cancer-promoting peptides are 
transported by plasma lipoproteins that have been 
identiﬁ  ed recently by a combination of proteomic 
approaches including 1-DE and 2-DE MALDI-
TOF, isotope-coded afﬁ  nity tag and Western blot 
analysis (Rezaee et al. 2006). This provides an 
unprecedented opportunity to apply current 
proteomics technology to cancer prognosis by 
monitoring serum and plasma protein levels after 
primary or adjuvant therapy.
In addition to the effort investigated in early 
detection, chemotherapy has been widely used in 
the treatment of various cancers for reducing 
cancer mortality. However, unpredictable effec-
tiveness and treatment toxicity continue to plague 
the chemotherapy. The novel treatments that are 
focused on speciﬁ  c targets in the signal transduc-
tion and/or metabolic pathways are extremely 
effective, and have less treatment associated 
toxicity. Herceptin
® (trastuzumab), a humanized 
monoclonal antibody which targets tumors over-
expressing the Her-2/neu receptor protein (Baselga 
et al. 2004; Ross et al. 2004ab), and Gleevec
® 
(imatinib mesylate), targeting cancers with bcr-abl 
gene translocation in chronic myeloid leukemia 
(Druker, 2004), are two of the best examples. The 
success of Herceptin and Gleevec has stimulated 
the development of pathway speciﬁ  c treatments 
for other types of cancer. Protein biomarker 
screening offers potential for subtyping cancers 
according to their unique protein proﬁ  les. Such 
signatures could be used to guide tailored 353
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treatment, avoid unnecessary toxicity, and reduce 
cost because of the selective nature of the treat-
ment. Signatures with biological signiﬁ  cance may 
not only improve cancer sub-classiﬁ  cation but also 
lead to the development of novel treatments (Hunt 
and Keyomarsi, 2005). 
Clinical proteomic approaches 
and platforms
Specimens for protein proﬁ  ling 
of cancer
Many types of biological specimens have been 
used in cancer proteomic research, such as cell 
lines, tumor tissue, serum, plasma, urine, salvia 
and nipple aspirate ﬂ  uid (NAF) for breast cancer 
(He et al. 2007; Shau et al. 2003). Tumor tissue 
may be an ideal source to study cancer proteomic 
signatures. Unfortunately tumor tissue can be 
difﬁ  cult to obtain and to preserve for proteomic 
analysis. Serum or plasma on the other hand has 
been most commonly used for biomarker research 
because sufﬁ  cient amounts of these samples are 
easily attainable by relatively non-invasive means, 
and frequently contain tumor markers, albeit 
maybe in low abundance. It is known that not only 
do tumors leak or secrete proteins into circulation, 
but also the surrounding stroma releases proteases 
and other mediators of tissue injury in response to 
the nearby tumor growth. The currently used tumor 
markers such as PSA, CA125, CEA, and alpha-
fetoprotein (AFP), are all examples of useful low 
abundance circulating cancer biomarkers that prob-
ably arise from the tumor and/or the surrounding 
stroma (Bast et al. 2001; Dhanasekaran et al. 
2001). 
However, serum/plasma proﬁ  ling is not without 
its challenges. As already alluded to, one major 
obstacle is the wide concentration range of the 
candidate markers that exceeds the dynamic
 range 
of any single analytical method or instrument 
(Domon and Aebersold, 2006). For example,
 it has 
been estimated that the concentration range of 
various serum
 proteins exceeds 10 orders of magni-
tude (Anderson and Anderson, 2002). Although 
this represents a daunting
 hurdle, recent techno-
logical developments have increased the dynamic 
range of analytical instrumentation, and new meth-
odological developments have reduced the 
threshold for protein detection to sub-nanogram 
levels (Domon and Aebersold, 2006). 
Fractionation of plasma and serum 
proteome
It is generally accepted that any method for detection 
of disease biomarkers in complex proteomes such 
as plasma and serum will require fractionation to 
reduce the complexity of the sample. This is 
considered essential even after the major abundant 
proteins, such as albumin, hemoglobin, immuno-
globulin, transferrin, complement, haptoglobin and 
others, have been depleted from the sample (Echan 
et al. 2005). A reﬂ  ection of this trend can be seen in 
a number of methods already reported for accom-
plishing this purpose. Numerous strategies have been 
developed including ion exchange based separations 
using the combination of strong cation exchange 
chromatography with reversed phase separations 
such as the multidimensional protein identiﬁ  cation 
technology (MUDPIT) developed by Yates and 
co-workers (Washburn et al. 2001), molecular weight 
based ﬁ  ltration (Hu et al. 2005), hydrophobicity 
based separation such as the use of reverse phase 
separations (Wang and Hanash, 2005), the capture 
of cysteine-containing peptides with biotinylated 
thiol reagents (Schrimpf et al. 2005), immobilizing 
of phosphorylated peptides by metal affinity 
chromatography (Corthals et al. 2005), dendrimer 
conjugation chemistry (Tao et al. 2005), glycopeptide 
capture (Zhang H. et al. 2005), activity-based protein 
profiling (ABPP) (Speers and Cravatt, 2004), 
ﬂ  uorophosphonate (FP)-based ABPP (Jessani et al. 
2005) targeting serine hydrolase, monolithic columns 
and Beckman’s PF2D fractionation instrument 
(Ratnayake et al. 2000). Also, there has been 
extensive work on microseparations for froteomic 
studies by Cheng Lee’s team (Li et al. 2003) and 
Smith’s group (Smith, 2006). Finally, Wall et al.
 
(2000) developed a unique two-dimensional all 
liquid-phase method combined with MS for protein 
profile analysis. With this method, proteins are 
fractionated by pI using isoelectric focusing (IEF) 
in the Rotofor cell and then separated by hydropho-
bicity using reverse phase-HPLC in the second 
dimension. All these separation or depletion 
procedures may help to remove interfering proteins 
and allow detection of biomarkers with lower 
concentrations for the analysis of cancer proteome.
Methodology and proteomic platforms
The basic principles of proteomics methods 
currently used in the application of cancer research 
including two-dimensional gel electrophoresis 354
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(2DE) and mass spectrometry (MS). Although 2DE 
is still a currently used tool for proteomic analysis, 
it has disadvantages regarding to its throughput, 
reproducibility, sensitivity and limited range of 
MW (<200 kDa) and pI (between 4 and 10), which 
limit the use of this method (Jenkins and 
Pennington, 2001). This review will focus on 
proteomic techniques based on mass spectrometry 
for cancer biomarker research. 
Since the discovery of new mass spectrometric 
ionization techniques for macromolecules almost 
20 years ago (Karas and Hillenkamp, 1988), many 
MS instruments have been developed and used in 
cancer biomarker research, for example, MALDI-
TOF MS, SELDI-TOF MS, LCMSMS and Qstar.
The term matrix-assisted laser desorption 
ionization (MALDI) was coined in 1985 by Franz 
Hillenkamp, Michael Karas and their colleagues 
(Karas et al. 1985). A matrix is used to protect 
biomolecules from being destroyed by direct laser 
beam. Using laser and matrix combination, ioniza-
tion of large biomolecules is possible (Karas and 
Hillenkamp, 1988). Further improvements were 
realized through the use of a 355 nm laser and the 
cinnamic acid derivatives ferulic acid, caffeic acid 
and sinapinic acid as the matrix (Beavis et al. 
1989). Today, MALDI-TOF MS became a popular 
and versatile method to analyze macromolecules 
from biological origin. In combination with 1DE 
and 2DE separation, MALDI-TOF is used to 
discover disease markers. For example, peptide 
mass ﬁ  ngerprint (PMF) is a protein identiﬁ  cation 
method based on the speciﬁ  city of a mass spectrum 
of the peptide mixture resulting from the digestion 
of a protein by an enzyme (e.g. trypsin). After 
proteolysis with a speciﬁ  c protease, proteins of 
different amino acid sequence produce a series of 
peptides masses, which can be detected by 
MALDI. The spectrum of identiﬁ  ed peptide masses 
is unique for a speciﬁ  c protein and is known as a 
mass ﬁ  ngerprint (Marvin et al. 2003). Searching 
the selected masses from the ﬁ  ngerprint against 
databases of known protein sequences (e.g. 
SwissProt-TrEMBL) enables the identiﬁ  cation of 
most proteins. 
SELDI technology was developed by Hutchens 
at Baylor College of Medicine in 1993 (Hutchens 
and Yip 1993). The technology was commercial-
ized by Ciphergen Biosystems Inc. in 1997 as the 
ProteinChip system. In this method, proteins are 
captured directly on a chemically derivatized 
MALDI plate. SELDI-TOF MS is similar to 
MALDI-TOF. They differ in how the matrix, or 
energy-absorbing molecule, is mixed with the 
protein sample. In MALDI, a protein or peptide 
sample is mixed with the matrix molecule in solu-
tion. Small amounts of the mixture are “spotted” 
on a surface and allowed to dry. The peptide sample 
and matrix co-crystallizes as the solvent evapo-
rates. In SELDI the protein mixture is spotted on 
a surface modiﬁ  ed with some chemical function-
ality. Some proteins in the sample bind to the 
surface, while the others are removed by washing. 
After washing the spotted sample, matrix is applied 
to the surface and allowed to crystallize with the 
sample peptides. Binding to the SELDI surface 
acts as a chromatography step and the subset of 
proteins that bind to the surface are easier to 
analyze. Common surfaces include CM10 (weak-
cation exchanger), H50 (hydrophobic surface, 
similar to C6-C12), IMAC30 (metal-binding 
surface), and Q10 (strong anion exchanger). 
Surfaces can also be functionalized with anti-
bodies, other proteins, or DNA.
SELDI allows the discrimination of peptides 
based on mass over charge ratio and provides a 
semi-quantitative evaluation, but cannot identify 
these peptides (Fung et al. 2001), which is the 
major disadvantage of this technology. So each 
protein of interest has to be puriﬁ  ed or enriched 
for identification purpose. The application of 
SELDI led to many exciting results (Petricoin 
et al. 2002), although results were not always 
reproducible (Editorial, 2004; Sorace and Zhan, 
2003; Baggerly et al. 2004). In Table 1, a list of 
several representative SELDI publications in 
cancer biomarker research was posted to reﬂ  ect 
the historical interest in this technology during the 
time period. While the enthusiasm in traditional 
SELDI declining, MALDI-TOF MS which is a 
particle-counting method that responds
 to molar 
abundance, still represent a useful tool for 
surveying small proteins
 and peptides. It is comple-
mentary to techniques
 such as electrophoresis and 
HPLC, which have an advantage for detecting
 
larger molecules (Hortin, 2006).
The methods used to explore cancer biomarkers 
will be discussed to facilitate the understanding of 
different techniques involved in different strate-
gies. This can be simply categorized into two 
groups: the “bottom up” (peptide level) and “top 
down” (intact protein level) approaches (Figure 1, 
from Dr. Weinberger of GenNext Technologies
TM 
Inc. with permission). The “bottom up” approach 355
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involves protein digestion followed by mass 
measurement of the resulting peptides and subse-
quent determination of partial sequence of the 
peptides. This data set is then compared against a 
data set composed of theoretical peptides, their 
masses and sequences for prediction of the identity 
of the peptide or protein in question. The result of 
this comparison is a report of the matches between 
the measured peptides and the theoretical peptides, 
usually listed in order of decreasing strength of the 
match. The  top down  approach ﬁ  rst involves 
mass measurement of the intact protein followed 
by attempts to identify the protein on the basis of 
this value and the measured molecular weights and 
sequences of the peptides derived from each 
digested protein. Careful and thorough examina-
tion of plasma/serum proteomes for disease 
biomarkers identiﬁ  cation should embrace both 
approaches because each has their own advantages 
and disadvantages. For example, the bottom-up 
approach has been successfully adapted to high 
throughput screening of complex proteomes but it 
lacks the molecular weight information of the intact 
protein and is less effective in recognizing and 
identifying the presence of PTMs (Bogdanov and 
Smith, 2005).
Few of the known protein biomarkers of cancer 
are exclusive for a speciﬁ  c malignancy, and most 
are also found in non-malignant conditions. 
Current cancer biomarkers are associated with an 
abnormal temporal, quantitative or conformational 
presentations (i.e. in incorrectly spliced or post-
translationally modiﬁ  ed forms), or combinations 
thereof. Although some of these associations are 
mere reﬂ  ections of abnormalities downstream of 
the real pathogenesis of the disease, it does not 
detract from their value as markers for cancer 
detection or stratiﬁ  cation. Consequently, the most 
useful cancer biomarkers are likely to be a suite of 
proteins that change in relative abundance during 
the disease process and during treatment. The 
implication of this is that the technology to detect 
these biomarkers must be both qualitative and 
sufﬁ  ciently quantitative to record subtle changes 
in the plasma/serum proteome in the face of a large 
number of other proteins or after depletion 
procedures. 
To this end, signiﬁ  cant investments have already 
been made in the exploration of the serum/plasma 
proteome to diagnose disease (Conrads et al. 2005, 
2006). Electrospray (Whitehouse et al. 1985; Mora 
et al. 2000; Fenn, 2003) and laser ionization mass 
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Figure 1. Proteomic biomarker discovery: integration of Top-Down and Bottom-Up approaches.356
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spectrometry have become important in this process 
as the most robust methods for ionizing a wide range 
of proteins and peptides prior to their mass spectro-
metric analysis. Several other important techniques 
have been used effectively to probe complex 
proteomes. Several important techniques are useful 
in this effort. The MUDPIT technology (Washburn 
et al. 2001) has already been described for the 
successful fractionation of complex proteomes. 
Tryptic digestion of the mixture is followed by two 
or more steps of sequential liquid chromatography 
coupled with ESI mass spectrometry. Isotope coded 
afﬁ  nity tags (ICAT, Gygi et al. 1999) and the newer, 
more successful technique of isobaric tags for rela-
tive and absolute quantiﬁ  cation (iTRAQ, Zhang Y. 
et al. 2005) both use stable isotope- labeled reagents 
for relatively quantitative comparisons of the 
proteomes of two or more samples. These strategies 
are based on the reaction of protein mixtures using 
reagents with speciﬁ  city toward certain functional 
groups such as the free sulfhydryl groups on cysteine 
residues. The reagents contain components with 
different molecular weights and an afﬁ  nity tag. 
Samples are separately reacted using the reagents 
with different molecular weights. The samples are 
then mixed. The same peptides present in multiple 
samples differ in molecular weight and can be 
distinguished by MS, and their relative signal inten-
sities accurately reﬂ  ect their relative abundances in 
the original samples. Extrapolation of such 
approaches for a comparison of relatively large 
numbers of samples, such as will be collected in the 
course of clinical trials, is an issue with which the 
ﬁ  eld has yet to grapple. Also iTRAQ technique 
labels all peptides in a sample making afﬁ  nity sepa-
rations unnecessary. Similarly, iTRAQ reagents are 
all isobaric, the difference in mass only becomes 
apparent due to the “reporter ion” in the MS/MS 
dimension. Finally, Wall et al.
 (2000) developed a 
unique two-dimensional all liquid-phase method 
combined with MS for protein proﬁ  le analysis. With 
this method, proteins are fractionated by pI using 
isoelectric focusing (IEF) in the Rotofor cell and 
then separated by hydrophobicity using reverse 
phase-HPLC in the second dimension. 
Reverse phase protein microarray 
(RPMA) in clinical phosphopro-
teomic proﬁ  ling
Besides mass spectrometry technology, protein 
microarray technology has also been widely used 
in proteomic studies. Protein microarrays can be 
divided into two broad categories: forward phase 
microarrays (FPMA) and reverse phase microar-
rays (RPMA). In the FPMA format, the analyte is 
captured from solution using a “bait” molecule 
immobilized on the array substrate. In contrast, in 
the RPMA format, the analyte is immobilized 
directly on the array substrate before being probed 
with an analyte-speciﬁ  c ligand, usually an antibody 
(Liotta et al. 2003; Templin et al. 2002; Mundinger 
et al. 2006). 
RPMA technology, ﬁ  rst introduced in 2001, is 
well suited to clinical proteomic research of 
oncology. One of the advantages of RPMA is to 
measure multiple analytes simultaneously from 
relatively smaller numbers of cells than required 
by mass spectrometry tools (Mundinger et al. 
2006). Another advantage is to study the phos-
phorylation and dephosphorylation events medi-
ated by protein kinases, which are critical in 
transduction networks and their aberrancies in 
cancer constitutes an exciting frontier in oncology 
(Pawson, 2002, Mundinger et al. 2006). Moreover, 
this method is highly sensitive with detection 
capabilities of 50 fg/l, or 1,000 to 5,000 molecules 
per spot (Liotta et al. 2003; Paweletz et al. 2001; 
Geho et al. 2005). However, the limitations of this 
analytical tool are that the quality of the arrays 
depends, as in all immunoassays, on the perfor-
mance of the primary antibody used. The endog-
enous biotin, immunoglobins, peroxidases, alkaline 
phosphatases, or ﬂ  uorescent proteins, contained in 
biological samples, have the potential to interfere 
with ampliﬁ  cation methods currently used for array 
detection (Mundinger et al. 2006). And ﬁ  nally since 
RPMA is dependent on antibodies, it cannot iden-
tify novel protein species, although it may identify 
novel network interactions among previously 
characterized proteins (Jones et al. 2006).
To date, several studies have utilized RPMA in 
the analysis of cancer signaling pathway alterations 
with clinical prostate (Paweletz et al. 2001; Grubb 
et al. 2003; Herrmann et al. 2003), ovarian 
(Wulfkuhle et al. 2003; Sheehan et al. 2005), 
colorectal (Belluco et al. 2005), breast cancer 
(Zhang DH et al. 2005ab; Cowherd et al. 2004, 
Wulfkuhle et al. 2002; Kersting et al. 2004) and 
lymphoma (Zha et al. 2004; Gulmann et al. 2005) 
specimens using RPMA. In these studies, pro-
survival, pro-mitogenic, and cell-cycle regulatory 
proteins, including phospho-Akt, PI3K, ERK, 
MAPK, PKCα, p38, STAT1, GSK3-β, cytochrome 357
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c oxidase, c-erbB2, and c-erbB1, phospho-PTEN, 
EGFR, have been studied.
Advantages and pitfalls of current 
proteomic technology
Proteomic technology enables high throughput 
analysis of protein biomarkers, and therefore 
provides an opportunity to identify and evaluate 
all potential protein biomarkers for early detection 
and to predict various tumor behaviors, including 
response to chemotherapy. This approach is gaining 
popularity among cancer researchers in their quest 
for cancer biomarkers with high diagnostic, prog-
nostic and predictive accuracy. However, despite 
initial excitement, skepticism about the method-
ology and the lack of concordance of results among 
labs and even within the same laboratories has 
eroded conﬁ  dence in this technology (Diamandis 
2004a, 2004b; Baggerly et al. 2004; Check, 2004; 
Villanueva and Tempst, 2004; Ransohoff, 2005). 
The simple fact that different research groups have 
found different discriminatory markers when 
analyzing similar samples suggests that the meth-
odology needs to be standardized to improve 
comparability, reproducibility and reliability of the 
ﬁ  ndings.
Apart from reproducibility and reliability of the 
mass spectrometric technology, other factors may 
also complicate the analytical effort. For example, 
sample collection, storage, and processing 
procedures can produce proteomic artifacts that 
could overshadow those representing of cancer 
(Villanueva et al. 2005; Banks et al. 2005; Karsan 
et al. 2005). Also the protein turnover rates in 
serum may be affected by liver and kidney function 
of each individual. It is known that cancer-
associated biomarkers are also released by 
conditions other than cancer, which lowers 
speciﬁ  city of the approach. Therefore, extreme 
sensitivity may be required because crucially 
important proteins often exist at low concentration 
in a particular type of cancer at its early stage. 
Detection of proteins released from tumor cells 
into the circulation is a challenging task, so prudent 
choices need to be made when selecting the proper 
technology and strategy. Depending on the 
experiment and the analyte, the sensitivity of 
proteomic LCMS experiments is now down to the 
50 fmol to 10 attomol of analyte-injected range. 
This translates to 5 ngm to 1 pgm of a 10 kDa 
protein. If the analyte were recovered from 1 ml 
of specimen, this limit of detection (LOD) is 
equivalent to or below the concentrations of most 
known circulating tumor markers, for example PSA 
(Maattanen et al. 2001). Therefore, mass spectro-
metric detection is now at the level of mid-range 
circulating biomarkers. Although further improve-
ments are needed before the low-range circulating 
biomarkers become accessible, the improvements 
in mass spectrometric LOD’s in the last few years 
have been remarkable. Nevertheless, discrimina-
tory peaks may include
 acute-phase reactants (i.e. 
molecules whose serum concentrations
 are 
increased with acute or chronic inflammatory
 
conditions) or other proteins or protein fragments 
that are
 released into the circulation by large 
organs, such as the liver,
 in response to the presence 
of a tumor or cancer, but not from cancer itself. 
Such epiphenomena can be mimicked by condition 
other than cancer including infection, inﬂ  amma-
tion, or malnutrition (Diamandis 2003a, 2003b, 
2004a, 2004b). 
In addition, numerous patient and environment-
related variables such as gender, age, genetics, 
ethnicity, body mass, medication, the presence of 
other conditions and diseases, psychological 
distress, menopausal status, and dietary/nutritional 
preferences, may all introduce artifacts, and the 
effect of these factors on the serum/plasma proteome 
have yet to be systematically investigated. 
In summary, designing a protein/peptide proﬁ  ling 
study must be rigorous to control for all important 
variables. Furthermore, standardized and optimized 
methodology is essential for achieving accurate 
measurement and meaningful analysis. This includes 
all involved steps extending from experimental 
design, specimen collection, storage and handling, 
throughout all methods used in the analytical chem-
istry and MS signal processing. Proper bioinformatics 
including analytical tools, data storage and sharing 
are required for data mining and validation. 
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